ClinicalTrials.gg
CompletedNCT03083639Updated Jun 14, 2019Results posted

A Study to Evaluate the Bioequivalence of Single Oral Dose of Esomeprazole Capsule and Tablet Formulation in Healthy Participants

A Phase 1 interventional study of Esomeprazole Capsule and Esomeprazole Tablet in Healthy Participants, sponsored by Takeda. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-06-14.

Sponsored by Takeda · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
52
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The purpose of this study is to determine the bioequivalence of esomeprazole 40 milligram (mg) tablets and capsules.

Read the detailed description

The drug being tested in this study is called esomeprazole. Esomeprazole is being tested in healthy participants in order to evaluate the bioequivalence between a single oral dose of esomeprazole tablet and capsule. The study will enroll 52 participants. Participants will be randomly assigned (by chance, like flipping a coin) to one of the two treatment sequences:

  • Esomeprazole 40 mg capsule + Esomeprazole 40 mg tablet
  • Esomeprazole 40 mg tablet + Esomeprazole 40 mg capsule

All participants will be asked to take one capsule or tablet on Day 1 of each Intervention Period based on the treatment sequence to which the participant has been assigned.

This single center trial will be conducted in the United States. The overall duration to participate in this study is 36 days. Participants will visit the clinic on Day -1 and remained confined until Day 1 of Intervention Period 1 and 2. A washout period of minimum 6 days will be maintained between the dose in each Intervention Period.

02

Conditions studied

  • Healthy Participants

Keywords

  • Drug Therapy
03

In context

Lead sponsor

Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.

Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Is a healthy adult male or female participant.
  2. Is aged 18 to 55 years, inclusive, at the time of and first study medication dose.
  3. Weighs at least 50 kilogram (kg) and has a (BMI) from 18.5 to 30 kilogram per square meter (kg/m\^2), inclusive at Screening and Day -1.

Exclusion criteria

Exclusion Criteria:

  1. Has uncontrolled, neurologic, cardiovascular, pulmonary, hepatic, renal, metabolic, gastrointestinal, or endocrine disease or other abnormality, which may impact the ability of the participant to participate or potentially confound the study results. It is the responsibility of the investigator to assess the clinical significance; however, consultation with the Takeda Medical Monitor may be warranted.
  2. Has a history of significant gastro intestinal (GI) disorders manifested with persistent, chronic or intermittent nausea, vomiting, diarrhea, or has a current or recent (within 6 months) GI disease that would influence the absorption of drugs (example, a history of malabsorption, severe esophageal reflux, peptic ulcer disease or erosive esophagitis), or any gastrointestinal-related surgical intervention..
  3. Has a known to any component of the formulation of esomeprazole capsules or tablets or compounds with the same mechanism of action (dexlansoprazole, lansoprazole, omeprazole, rabeprazole, pantoprazole), or related compounds.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
52 participants (actual)

Study arms

  • Experimental
    Esomeprazole 40 mg Capsule + Esomeprazole 40 mg Tablet

    Esomeprazole 40 mg, capsule, orally, once on Day 1 of Intervention Period 1, followed by 6 days of washout period, followed by esomeprazole 40 mg tablet, orally, once on Day 1 of Intervention Period 2.

    Drug: Esomeprazole Capsule · Drug: Esomeprazole Tablet

  • Experimental
    Esomeprazole 40 mg Tablet + Esomeprazole 40 mg Capsule

    Esomeprazole 40 mg, tablet, orally, once on Day 1 of Intervention Period 1, followed by 6 days of washout period, followed by esomeprazole 40 mg capsule, orally, once on Day 1 of Intervention Period 2.

    Drug: Esomeprazole Capsule · Drug: Esomeprazole Tablet

Interventions

06

What researchers measure

Primary outcomes

  1. AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Esomeprazole

    Time frame: Day 1 pre-dose and at multiple time points (up to 10 hours) post-dose

  2. AUCt: Area Under the Plasma Concentration-time Curve From Time 0 to Time t for Esomeprazole

    Time frame: Day 1 pre-dose and at multiple time points (up to 10 hours) post-dose

  3. Cmax: Maximum Observed Plasma Concentration for Esomeprazole

    Time frame: Day 1 pre-dose and at multiple time points (up to 10 hours) post-dose

07

Results

Posted Jun 14, 2019

Participant flow

Participants took part in the study at 1 investigative site in the United States from 27 March 2017 to 13 May 2017.

Intervention Period 1 (1 Day)
Participant flow — Intervention Period 1 (1 Day)
MilestoneRegimen A + Regimen BRegimen B + Regimen A
Started2626
Completed2626
Not completed00
Washout Period (at Least 6 Days)
Participant flow — Washout Period (at Least 6 Days)
MilestoneRegimen A + Regimen BRegimen B + Regimen A
Started2626
Completed2525
Not completed11
Withdrew: Pregnancy01
Withdrew: Lost to follow-up10
Intervention Period 2 (1 Day)
Participant flow — Intervention Period 2 (1 Day)
MilestoneRegimen A + Regimen BRegimen B + Regimen A
Started2525
Completed2525
Not completed00

Outcome measures

PrimaryAUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Esomeprazole
Time frame:
Day 1 pre-dose and at multiple time points (up to 10 hours) post-dose
Reported as:
Geometric mean · hour*nanogram per milliliter (h*ng/mL)
AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Esomeprazole
hour*nanogram per milliliter (h*ng/mL)Regimen ARegimen B
AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Esomeprazole1908.0 ± 66.01922.2 ± 57.9
Statistical analysis
  • Regimen A vs Regimen B · Point estimate: 1.018 · 90% CI 0.969 to 1.070
PrimaryAUCt: Area Under the Plasma Concentration-time Curve From Time 0 to Time t for Esomeprazole
Time frame:
Day 1 pre-dose and at multiple time points (up to 10 hours) post-dose
Reported as:
Geometric mean · h*ng/mL
AUCt: Area Under the Plasma Concentration-time Curve From Time 0 to Time t for Esomeprazole
h*ng/mLRegimen ARegimen B
AUCt: Area Under the Plasma Concentration-time Curve From Time 0 to Time t for Esomeprazole1884.6 ± 64.31882.6 ± 57.5
Statistical analysis
  • Regimen A vs Regimen B · Point estimate: 0.993 · 90% CI 0.939 to 1.050
PrimaryCmax: Maximum Observed Plasma Concentration for Esomeprazole
Time frame:
Day 1 pre-dose and at multiple time points (up to 10 hours) post-dose
Reported as:
Geometric mean · nanogram per milliliter (ng/mL)
Cmax: Maximum Observed Plasma Concentration for Esomeprazole
nanogram per milliliter (ng/mL)Regimen ARegimen B
Cmax: Maximum Observed Plasma Concentration for Esomeprazole933.29 ± 44.5872.38 ± 43.5
Statistical analysis
  • Regimen A vs Regimen B · Point estimate: 0.942 · 90% CI 0.880 to 1.009

Adverse events

Collected over Treatment-emergent adverse events are adverse events that started after the first dose of study drug and no more than 30 days after the last dose of study drug. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Regimen A0/51 (0%)0/51 (0%)4/51 (7.8%)
Regimen B0/51 (0%)0/51 (0%)3/51 (5.9%)
Most frequent other events
Most frequent other events
EventRegimen ARegimen B
HeadacheNervous system disorders3/512/51
DysmenorrhoeaReproductive system and breast disorders0/511/51
Nasal congestionRespiratory, thoracic and mediastinal disorders1/511/51

Baseline characteristics

The safety analysis set included all participants who were randomized and received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)Regimen A + Regimen BRegimen B + Regimen ATotal
Mean32.4 ± 9.6433.3 ± 7.8332.8 ± 8.71
Sex: Female, Male
Sex: Female, Male(Participants)Regimen A + Regimen BRegimen B + Regimen ATotal
Female91120
Male171532
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Regimen A + Regimen BRegimen B + Regimen ATotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American81119
White181331
More than one race022
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(Participants)Regimen A + Regimen BRegimen B + Regimen ATotal
United States262652
Weight
Weight(kilogram)Regimen A + Regimen BRegimen B + Regimen ATotal
Mean73.3 ± 12.8375.3 ± 13.3774.3 ± 13.01
Height
Height(centimeter)Regimen A + Regimen BRegimen B + Regimen ATotal
Mean173.4 ± 10.36170.7 ± 10.95172.0 ± 10.65
Body Mass Index (BMI)
Body Mass Index (BMI)(kilogram per square meter (kg/m^2))Regimen A + Regimen BRegimen B + Regimen ATotal
Mean24.3 ± 2.7725.7 ± 2.8925.0 ± 2.89
Smoking Status
Smoking Status(Participants)Regimen A + Regimen BRegimen B + Regimen ATotal
Never smoked182442
Ex-smoker8210
08

Study locations

1 site
  • Pharmaceutical Research Associates, Inc.
    Lenexa, Kansas 66219, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2017 to primary completion in May 2017, 1 month.

Results were first posted in Jun 2019, 2 years 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 14, 2017
First posted
Mar 20, 2017
StartActual
Mar 27, 2017
Primary completionActual
May 13, 2017
CompletionActual
May 13, 2017
Results first posted
Jun 14, 2019
Last update
Jun 14, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 14, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03083639
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Mar 20, 2017
Start date
Mar 27, 2017
Primary completion
May 13, 2017
Completion
May 13, 2017
Results posted
Jun 14, 2019
Last update
Jun 14, 2019

Study contacts

Medical Director
study director · Takeda

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Esomeprazole

Start the discussion